CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

onasemnogene abeparvovec

Last Updated: July 28, 2020
Result type: Reports
Project Number: SG0649-000
Product Line: Common Drug Review

Generic Name: onasemnogene abeparvovec

Brand Name: Zolgensma

Manufacturer: Novartis Pharmaceuticals Canada Inc.

Indications: Spinal muscular atrophy (SMA), pediatrics

Manufacturer Requested Reimbursement Criteria1: Zolgensma is an adeno-associated virus (AVV) vector-based gene therapy indicated for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene

Submission Type: New

Project Status: Active

Companion Diagnostics: No

Fee Schedule: Schedule E

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input openMay 26, 2020
Call for patient input closedJuly 15, 2020

- Patient input submission received from Cure SMA Canada and Muscular Dystrophy Canada (MDC)

Submission receivedJune 25, 2020
Submission acceptedJuly 10, 2020
Review initiatedJuly 13, 2020
Draft CADTH review report(s) provided to sponsor for commentSeptember 25, 2020
Deadline for sponsors commentsOctober 06, 2020
CADTH responses on draft review report(s) provided to sponsorNovember 06, 2020
Expert committee meeting (initial)November 18, 2020
Draft recommendation issuedNovember 30, 2020
December 02, 2020